person · Reporting owner

GADICKE ANSBERT

Disclosed activity across 13 companies

Tapewire entity: 2481
SEC CIK: 0001134655

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aktis Oncology, Inc.AKTS · Entity 4711	10% owner	January 12, 2026	January 14, 2026
Cullinan Therapeutics, Inc.CGEM · Entity 4766	10% owner · Former Director	December 31, 2021	February 10, 2023
Dyne Therapeutics, Inc.DYN · Entity 3948	10% owner	September 21, 2020	September 23, 2020
Harpoon Therapeutics, Inc.HARP · Entity 11424	10% owner	May 28, 2021	June 02, 2021
Kalaris Therapeutics, Inc.ALVR · Entity 6805	Director · 10% owner	July 28, 2022	August 01, 2022
Oncorus, Inc.ONCR · Entity 112213	10% owner	October 06, 2020	October 08, 2020
RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693	10% owner	October 10, 2017	October 11, 2017
Radius Health, Inc.RDUS · Entity 124173	Director	February 17, 2017	February 22, 2017
Repare Therapeutics Inc.RPTX · Entity 68433	10% owner	July 09, 2021	July 13, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aktis Oncology, Inc.

Report date January 12, 2026 · Filed January 14, 2026

Jointly reported with MPM ASSET MANAGEMENT LLC, Oncology Impact Private Investment Fund 2, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,655,971	Reported balance After 2026-01-12 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-01-12 · Conversion · Acquired 1,314,262 · Balance 1,655,971 F1: The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"), 119,478 by MPM Oncology Innovations Fund, L.P. ("MPM Oncology") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. ("MPM Oncology Impact"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing member of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact. F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The shares are held as follows: 341,709 by MPM Asset Management LLC ("MPM AM"), 556,810 by BV 2018, 29,593 by BV 2018(B), 10,988 by AM BV2018, 119,478 by MPM Oncology and 597,393 by MPM Oncology Impact. Dr. Gadicke is the manager of MPM AM.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	7,570,168	Reported balance After 2026-01-12 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2026-01-12 · Conversion · Acquired 5,914,197 · Balance 7,570,168 F5: The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact. F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F6: The shares are held as follows: 341,709 by MPM AM, 3,062,458 by BV 2018, 162,763 by BV 2018(B), 60,440 by AM BV2018, 657,132 by MPM Oncology and 3,285,666 by MPM Oncology Impact.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	9,147,287	Reported balance After 2026-01-12 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2026-01-12 · Conversion · Acquired 1,577,119 · Balance 9,147,287 F7: The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact. F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8: The shares are held as follows: 341,709 by MPM AM, 3,730,631 by BV 2018, 198,275 by BV 2018(B), 73,627 by AM BV2018, 800,506 by MPM Oncology and 4,002,539 by MPM Oncology Impact.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	10,260,064	Reported balance After 2026-01-12 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2026-01-12 · Purchase · Acquired 1,112,777 · Balance 10,260,064 F9: The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B), 4,284 by AM BV2018, 46,574 by MPM Oncology and 833,333 by MPM Oncology Impact. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F10: The shares are held as follows: 341,709 by MPM AM, 3,950,528 by BV 2018, 206,964 by BV 2018(B), 77,911 by AM BV2018, 847,080 by MPM Oncology and 4,835,872 by MPM Oncology Impact.
Series Seed Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-01-12 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-01-12 · Conversion · Disposed 5,000,000 · Balance 0 F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F1: The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"), 119,478 by MPM Oncology Innovations Fund, L.P. ("MPM Oncology") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. ("MPM Oncology Impact"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing member of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-01-12 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-01-12 · Conversion · Disposed 22,500,000 · Balance 0 F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5: The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact.
Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-01-12 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-01-12 · Conversion · Disposed 6,000,000 · Balance 0 F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F7: The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"), 119,478 by MPM Oncology Innovations Fund, L.P. ("MPM Oncology") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. ("MPM Oncology Impact"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing member of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact.

F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date.

F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F4: The shares are held as follows: 341,709 by MPM Asset Management LLC ("MPM AM"), 556,810 by BV 2018, 29,593 by BV 2018(B), 10,988 by AM BV2018, 119,478 by MPM Oncology and 597,393 by MPM Oncology Impact. Dr. Gadicke is the manager of MPM AM.

F5: The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact.

F6: The shares are held as follows: 341,709 by MPM AM, 3,062,458 by BV 2018, 162,763 by BV 2018(B), 60,440 by AM BV2018, 657,132 by MPM Oncology and 3,285,666 by MPM Oncology Impact.

F7: The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact.

F8: The shares are held as follows: 341,709 by MPM AM, 3,730,631 by BV 2018, 198,275 by BV 2018(B), 73,627 by AM BV2018, 800,506 by MPM Oncology and 4,002,539 by MPM Oncology Impact.

F9: The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B), 4,284 by AM BV2018, 46,574 by MPM Oncology and 833,333 by MPM Oncology Impact.

F10: The shares are held as follows: 341,709 by MPM AM, 3,950,528 by BV 2018, 206,964 by BV 2018(B), 77,911 by AM BV2018, 847,080 by MPM Oncology and 4,835,872 by MPM Oncology Impact.

Cullinan Therapeutics, Inc.

Report date December 31, 2021 · Filed February 10, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	595,489	Reported balance After 2021-12-21 transaction · row 1 1 source row Row 1 · 2021-12-21 · Exercise / conversion · Acquired 350,938 · Balance 595,489
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.30 · Expires 2030-10-28	Direct	0	Reported balance After 2021-12-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-12-21 · Exercise / conversion · Disposed 262,114 · Balance 0 F3: These options are fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.30 · Expires 2030-10-28	Direct	0	Reported balance After 2021-12-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-12-21 · Exercise / conversion · Disposed 88,824 · Balance 0 F3: These options are fully vested.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	7,648,268	Reported balance Holding disclosure · report date 2021-12-31 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 7,648,268 F1: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC.

F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F3: These options are fully vested.

Dyne Therapeutics, Inc.

Report date September 21, 2020 · Filed September 23, 2020

Jointly reported with MPM BIOVENTURES 2018, L.P., MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC, MPM BioVentures 2018 GP LLC, MPM BioVentures 2018 LLC, EVNIN LUKE, Foley Todd

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	4,614,943	Reported balance After 2020-09-21 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-09-21 · Conversion · Acquired 4,614,943 · Balance 4,614,943 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectSee footnote	245,279	Reported balance After 2020-09-21 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2020-09-21 · Conversion · Acquired 245,279 · Balance 245,279 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectSee footnote	91,081	Reported balance After 2020-09-21 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2020-09-21 · Conversion · Acquired 91,081 · Balance 91,081 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-09-21 · Conversion · Disposed 13,980,992 · Balance 0 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-09-21 · Conversion · Disposed 743,076 · Balance 0 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-09-21 · Conversion · Disposed 275,932 · Balance 0 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-09-21 · Conversion · Disposed 1,326,313 · Balance 0 F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-09-21 · Conversion · Disposed 70,492 · Balance 0 F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-09-21 · Conversion · Disposed 26,176 · Balance 0 F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F2: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any.

F3: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any.

F4: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any.

F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

Harpoon Therapeutics, Inc.

Report date May 28, 2021 · Filed June 02, 2021

Jointly reported with Oncology Impact Fund (Cayman) Management L.P., MPM BIOIMPACT LLC, MPM Oncology Impact Management GP LLC, UBS Oncology Impact Fund L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	6,374,904	Reported balance After 2021-05-28 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-05-28 · Sale · Disposed 10,685 · Balance 6,374,904 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2: The shares were sold as follows: 9,392 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 1,293 by MPM Asset Management LLC ("AM LLC"). F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 231,110 by AM LLC and 3,237,851 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	6,371,804	Reported balance After 2021-05-28 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2021-05-28 · Sale · Disposed 3,100 · Balance 6,371,804 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F5: The shares were sold as follows: 2,725 by UBS Oncology and 375 by AM LLC. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.58 to $22.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,735 by AM LLC and 3,235,126 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	6,371,704	Reported balance After 2021-05-28 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2021-05-28 · Sale · Disposed 100 · Balance 6,371,704 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F8: The shares were sold as follows: 88 by UBS Oncology and 12 by AM LLC. F9: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,723 by AM LLC and 3,235,038 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	6,353,213	Reported balance After 2021-06-01 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2021-06-01 · Sale · Disposed 18,491 · Balance 6,353,213 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F10: The shares were sold as follows: 16,253 by UBS Oncology and 2,238 by AM LLC. F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F12: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 228,485 by AM LLC and 3,218,785 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	6,328,095	Reported balance After 2021-06-02 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2021-06-02 · Sale · Disposed 25,118 · Balance 6,328,095 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F13: The shares were sold as follows: 22,078 by UBS Oncology and 3,040 by AM LLC. F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.24 to $20.76 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F15: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 225,445 by AM LLC and 3,196,707 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021.

F2: The shares were sold as follows: 9,392 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 1,293 by MPM Asset Management LLC ("AM LLC").

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 231,110 by AM LLC and 3,237,851 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F5: The shares were sold as follows: 2,725 by UBS Oncology and 375 by AM LLC.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.58 to $22.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,735 by AM LLC and 3,235,126 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F8: The shares were sold as follows: 88 by UBS Oncology and 12 by AM LLC.

F9: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,723 by AM LLC and 3,235,038 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F10: The shares were sold as follows: 16,253 by UBS Oncology and 2,238 by AM LLC.

F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F12: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 228,485 by AM LLC and 3,218,785 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F13: The shares were sold as follows: 22,078 by UBS Oncology and 3,040 by AM LLC.

F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.24 to $20.76 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F15: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 225,445 by AM LLC and 3,196,707 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

Kalaris Therapeutics, Inc.

Report date July 28, 2022 · Filed August 01, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy ElevateBio LLC	16,674,766	Reported balance After 2022-07-28 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2022-07-28 · Grant · Acquired 3,253,796 · Balance 16,674,766 F1: On July 28, 2022, ElevateBio LLC ("ElevateBio") acquired 3,253,796 shares of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share. F2: Shares held by ElevateBio. The Reporting Person is a director of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	Direct	30,197	Reported balance Holding disclosure · report date 2022-07-28 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 30,197

Filing footnotes · ownership attribution and instrument terms

F1: On July 28, 2022, ElevateBio LLC ("ElevateBio") acquired 3,253,796 shares of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share.

F2: Shares held by ElevateBio. The Reporting Person is a director of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Oncorus, Inc.

Report date October 06, 2020 · Filed October 08, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,899,702	Reported balance After 2020-10-06 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2020-10-06 · Conversion · Acquired 1,783,879 · Balance 1,899,702 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F3: The shares are held as follows: 1,382,943 by MPM BioVentures 2014, L.P. ("BV 2014"), 92,239 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 50,164 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,924 by MPM Sunstates Fund, L.P. ("MPM SunStates"), 33,609 by MPM Asset Management Investors Sunstates Fund LLC ("AM SunStates") and 115,823 by MPM Asset Management LLC ("AM LLC"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC ("SunStates GP") are the direct and indirect general partners of MPM SunStates. SunStates GP is the manager of AM SunStates. Luke Evnin, Ansbert Gadicke and Todd Foley are the managing directors of BV LLC, Luke Evnin and Anbsert Gadicke are the members of AM LLC and Ansbert Gadicke is a member of SunStates GP.
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,525,348	Reported balance After 2020-10-06 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2020-10-06 · Conversion · Acquired 1,525,348 · Balance 1,525,348 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,675,677	Reported balance After 2020-10-06 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2020-10-06 · Conversion · Acquired 775,975 · Balance 2,675,677 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5: The shares are held as follows: 2,018,001 by BV 2014, 134,595 by BV 2014(B), 73,199 by AM BV2014, 290,632 by MPM SunStates, 43,427 by AM SunStates and 115,823 by AM LLC.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,225,801	Reported balance After 2020-10-06 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2020-10-06 · Conversion · Acquired 700,453 · Balance 2,225,801 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,849,453	Reported balance After 2020-10-06 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2020-10-06 · Purchase · Acquired 173,776 · Balance 2,849,453 F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F6: The shares are held as follows: 2,155,108 by BV 2014, 143,740 by BV 2014(B), 78,172 by AM BV2014, 310,251 by MPM SunStates, 46,359 by AM SunStates and 115,823 by AM LLC.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,377,025	Reported balance After 2020-10-06 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2020-10-06 · Purchase · Acquired 151,224 · Balance 2,377,025 F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-10-06 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-10-06 · Conversion · Acquired 1,783,879 · Balance 0 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F7: The shares are held as follows: 1,382,943 by BV 2014, 92,239 by BV 2014(B), 50,164 by AM BV2014, 224,924 by MPM SunStates and 33,609 by AM SunStates.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-10-06 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-10-06 · Conversion · Acquired 1,525,348 · Balance 0 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-10-06 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-10-06 · Conversion · Acquired 775,975 · Balance 0 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8: The shares are held as follows: 635,058 by BV 2014, 42,356 by BV 2014(B), 23,035 by AM BV2014, 65,708 by MPM SunStates and 9,818 by AM SunStates.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-10-06 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-10-06 · Conversion · Acquired 700,453 · Balance 0 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.

F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F3: The shares are held as follows: 1,382,943 by MPM BioVentures 2014, L.P. ("BV 2014"), 92,239 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 50,164 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,924 by MPM Sunstates Fund, L.P. ("MPM SunStates"), 33,609 by MPM Asset Management Investors Sunstates Fund LLC ("AM SunStates") and 115,823 by MPM Asset Management LLC ("AM LLC"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC ("SunStates GP") are the direct and indirect general partners of MPM SunStates. SunStates GP is the manager of AM SunStates. Luke Evnin, Ansbert Gadicke and Todd Foley are the managing directors of BV LLC, Luke Evnin and Anbsert Gadicke are the members of AM LLC and Ansbert Gadicke is a member of SunStates GP.

F4: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC.

F5: The shares are held as follows: 2,018,001 by BV 2014, 134,595 by BV 2014(B), 73,199 by AM BV2014, 290,632 by MPM SunStates, 43,427 by AM SunStates and 115,823 by AM LLC.

F6: The shares are held as follows: 2,155,108 by BV 2014, 143,740 by BV 2014(B), 78,172 by AM BV2014, 310,251 by MPM SunStates, 46,359 by AM SunStates and 115,823 by AM LLC.

F7: The shares are held as follows: 1,382,943 by BV 2014, 92,239 by BV 2014(B), 50,164 by AM BV2014, 224,924 by MPM SunStates and 33,609 by AM SunStates.

F8: The shares are held as follows: 635,058 by BV 2014, 42,356 by BV 2014(B), 23,035 by AM BV2014, 65,708 by MPM SunStates and 9,818 by AM SunStates.

RHYTHM PHARMACEUTICALS, INC.

Report date October 10, 2017 · Filed October 11, 2017

Jointly reported with MPM BIOVENTURES V, L.P., EVNIN LUKE, MPM ASSET MANAGEMENT INVESTORS BV5 LLC, MPM BIOVENTURES V GP LLC, MPM BIOVENTURES V LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	2,596,392	Reported balance After 2017-10-10 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2017-10-10 · Conversion · Acquired 2,567,014 · Balance 2,596,392 F1: Each share of preferred stock converted into approximately 0.10905125 shares of common stock upon the closing of the issuer's initial public offering. The shares had no expiration date. F2: The shares are held as follows: 2,499,299 by MPM BioVentures V, L.P. ("BV V") and 97,093 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. Mr. Foley is a director of the Issuer and has separately filed a Form 4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	2,696,392	Reported balance After 2017-10-10 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2017-10-10 · Purchase · Acquired 100,000 · Balance 2,696,392 F3: Shares were purchased as follows: 96,260 by BV V and 3,740 by AM BV5. F4: Shares are held as follows: 2,595,559 by BV V and 100,833 by AM BV5. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2017-10-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-10-10 · Conversion · Disposed 7,651,831 · Balance 0 F1: Each share of preferred stock converted into approximately 0.10905125 shares of common stock upon the closing of the issuer's initial public offering. The shares had no expiration date. F5: The shares of Series A Preferred Stock were held as follows: 7,365,688 by BV V and 286,143 by AM BV5.
Series A-1 Junior Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2017-10-10 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-10-10 · Conversion · Disposed 15,887,703 · Balance 0 F1: Each share of preferred stock converted into approximately 0.10905125 shares of common stock upon the closing of the issuer's initial public offering. The shares had no expiration date. F6: The shares of Series A-1 Junior Preferred Stock were held as follows: 15,293,569 by BV V and 594,134 by AM BV5.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of preferred stock converted into approximately 0.10905125 shares of common stock upon the closing of the issuer's initial public offering. The shares had no expiration date.

F2: The shares are held as follows: 2,499,299 by MPM BioVentures V, L.P. ("BV V") and 97,093 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. Mr. Foley is a director of the Issuer and has separately filed a Form 4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

F3: Shares were purchased as follows: 96,260 by BV V and 3,740 by AM BV5.

F4: Shares are held as follows: 2,595,559 by BV V and 100,833 by AM BV5. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

F5: The shares of Series A Preferred Stock were held as follows: 7,365,688 by BV V and 286,143 by AM BV5.

F6: The shares of Series A-1 Junior Preferred Stock were held as follows: 15,293,569 by BV V and 594,134 by AM BV5.

Radius Health, Inc.

Report date February 17, 2017 · Filed February 22, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.65 · Expires 2027-02-16	Direct	27,500	Reported balance After 2017-02-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-02-17 · Grant · Acquired 27,500 · Balance 27,500 F1: The option vests in full on February 17, 2018, subject to continued service to the Issuer through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in full on February 17, 2018, subject to continued service to the Issuer through such date.

Repare Therapeutics Inc.

Report date July 09, 2021 · Filed July 13, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	IndirectSee Footnote	3,940,497	Reported balance After 2021-07-09 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2021-07-09 · Sale · Disposed 4,067 · Balance 3,940,497 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F2: The shares were sold as follows: 1,732 by MPM BioVentures 2014, L.P. ("BV 2014"), 60 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 2,275 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: The shares are held as follows: 2,061,400 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 70,952 by AM BV2014 and 1,672,302 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a managing director of BV LLC. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the Managing Member of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Common SharesSEC Table I · non-derivative	IndirectSee Footnote	3,883,196	Reported balance After 2021-07-12 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2021-07-12 · Sale · Disposed 57,301 · Balance 3,883,196 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F5: The shares were sold as follows: 24,408 by BV 2014, 838 by AM BV2014 and 32,055 by UBS Oncology. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.05 to $34.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7: The shares are held as follows: 2,036,992 by BV 2014, 135,843 by BV 2014(B), 70,114 by AM BV2014 and 1,640,247 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Common SharesSEC Table I · non-derivative	IndirectSee Footnote	3,882,485	Reported balance After 2021-07-12 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2021-07-12 · Sale · Disposed 711 · Balance 3,882,485 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F8: The shares were sold as follows: 303 by BV 2014, 10 by AM BV2014 and 398 by UBS Oncology. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.055 to $34.135 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10: The shares are held as follows: 2,036,689 by BV 2014, 135,843 by BV 2014(B), 70,104 by AM BV2014 and 1,639,849 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021.

F2: The shares were sold as follows: 1,732 by MPM BioVentures 2014, L.P. ("BV 2014"), 60 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 2,275 by UBS Oncology Impact Fund L.P. ("UBS Oncology").

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The shares are held as follows: 2,061,400 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 70,952 by AM BV2014 and 1,672,302 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a managing director of BV LLC. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the Managing Member of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F5: The shares were sold as follows: 24,408 by BV 2014, 838 by AM BV2014 and 32,055 by UBS Oncology.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.05 to $34.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7: The shares are held as follows: 2,036,992 by BV 2014, 135,843 by BV 2014(B), 70,114 by AM BV2014 and 1,640,247 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F8: The shares were sold as follows: 303 by BV 2014, 10 by AM BV2014 and 398 by UBS Oncology.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.055 to $34.135 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F10: The shares are held as follows: 2,036,689 by BV 2014, 135,843 by BV 2014(B), 70,104 by AM BV2014 and 1,639,849 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Entrada Therapeutics, Inc.

Report date September 04, 2026 · Filed September 09, 2026

Jointly reported with MPM BioVentures 2014, L.P., EVNIN LUKE, Foley Todd, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC

Section 16 reporting ended · disclosed 2026-09-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	4,106,452	Reported balance After 2026-09-04 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-09-04 · Sale · Disposed 38,500 · Balance 4,106,452 F1: The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,166 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 602 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 17,942 by MPM BioVentures 2018, L.P. ("BV 2018"), 954 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 354 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. F2: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3: The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018. F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,913,952	Reported balance After 2026-09-08 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2026-09-08 · Sale · Disposed 192,500 · Balance 3,913,952 F5: The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018. F6: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F7: The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,885,115	Reported balance After 2026-09-09 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2026-09-09 · Sale · Disposed 28,837 · Balance 3,885,115 F8: The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018. F9: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F10: The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,166 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 602 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 17,942 by MPM BioVentures 2018, L.P. ("BV 2018"), 954 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 354 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.

F2: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

F3: The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018.

F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

F5: The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018.

F6: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

F7: The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018.

F8: The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018.

F9: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

F10: The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018.

TCR2 THERAPEUTICS INC.

Report date June 01, 2023 · Filed June 05, 2023

Section 16 reporting ended · disclosed 2023-06-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2023-06-01 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2023-06-01 · Other · Disposed 304,001 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). F3: The shares were held by MPM Asset Management LLC ("AM LLC"). The reporting person is a member of AM LLC and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2023-06-01 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2023-06-01 · Other · Disposed 3,854,963 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). F4: The shares were held as follows: 3,056,272 by MPM BioVentures 2014, L.P. ("BV 2014"), 203,846 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 110,859 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 421,070 by MPM SunStates Fund, L.P. ("MPM SunStates") and 62,916 by MPM Asset Management Investors Sunstates Fund LLC ("AM SunStates"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B) and BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC ("SunStates GP") are the direct and indirect general partners of MPM SunStates and SunStates GP is the manager of AM SunStates. The reporting person is a managing director of BV LLC and a member of SunStates GP and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2023-06-01 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2023-06-01 · Other · Disposed 3,370,982 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). F5: The shares were held by UBS Oncology Impact Fund L.P. ("UBS Oncology"). BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. The reporting person is the managing partner of BioImpact and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").

F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares").

F3: The shares were held by MPM Asset Management LLC ("AM LLC"). The reporting person is a member of AM LLC and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

F4: The shares were held as follows: 3,056,272 by MPM BioVentures 2014, L.P. ("BV 2014"), 203,846 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 110,859 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 421,070 by MPM SunStates Fund, L.P. ("MPM SunStates") and 62,916 by MPM Asset Management Investors Sunstates Fund LLC ("AM SunStates"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B) and BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC ("SunStates GP") are the direct and indirect general partners of MPM SunStates and SunStates GP is the manager of AM SunStates. The reporting person is a managing director of BV LLC and a member of SunStates GP and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

F5: The shares were held by UBS Oncology Impact Fund L.P. ("UBS Oncology"). BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. The reporting person is the managing partner of BioImpact and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Werewolf Therapeutics, Inc.

Report date December 02, 2025 · Filed December 04, 2025

Jointly reported with MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BIOIMPACT LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC

Section 16 reporting ended · disclosed 2025-12-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	4,924,566	Reported balance After 2025-12-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-12-02 · Sale · Disposed 59,277 · Balance 4,924,566 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2: The shares were sold as follows: 4,070 by MPM Asset Management LLC ("AM LLC"), 25,712 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,715 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 884 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,662 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 21,234 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5: The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014, 468,282 by MPM OIF and 1,766,146 by UBS Oncology.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	4,867,341	Reported balance After 2025-12-03 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2025-12-03 · Sale · Disposed 57,225 · Balance 4,867,341 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6: The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014, 5,466 by MPM OIF and 20,499 by UBS Oncology. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8: The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014, 462,816 by MPM OIF and 1,745,647 by UBS Oncology.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	4,784,111	Reported balance After 2025-12-04 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2025-12-04 · Sale · Disposed 83,230 · Balance 4,784,111 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9: The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014, 7,950 by MPM OIF and 29,814 by UBS Oncology. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11: The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014, 454,866 by MPM OIF and 1,715,833 by UBS Oncology.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.

F2: The shares were sold as follows: 4,070 by MPM Asset Management LLC ("AM LLC"), 25,712 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,715 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 884 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,662 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 21,234 by UBS Oncology Impact Fund L.P. ("UBS Oncology").

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F5: The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014, 468,282 by MPM OIF and 1,766,146 by UBS Oncology.

F6: The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014, 5,466 by MPM OIF and 20,499 by UBS Oncology.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8: The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014, 462,816 by MPM OIF and 1,745,647 by UBS Oncology.

F9: The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014, 7,950 by MPM OIF and 29,814 by UBS Oncology.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F11: The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014, 454,866 by MPM OIF and 1,715,833 by UBS Oncology.

iTeos Therapeutics, Inc.

Report date May 13, 2025 · Filed May 15, 2025

Jointly reported with MPM BIOIMPACT LLC, Oncology Impact Fund (Cayman) Management L.P., UBS Oncology Impact Fund L.P.

Section 16 reporting ended · disclosed 2025-05-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,452,797	Reported balance After 2025-05-13 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-05-13 · Sale · Disposed 1,031,931 · Balance 3,452,797 F1: The shares were sold as follows: 355,406 by MPM BioVentures 2014, L.P. ("BV 2014"), 22,386 by MPM BioVentures 2014 (B), L.P. ("BV 2014(B)"), 12,233 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,467 by MPM BioVentures 2018, L.P. ("BV 2018"), 11,267 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 4,432 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 401,740 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F2: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: The shares are held as follows: 1,189,174 by BV 2014, 74,903 by BV 2014(B), 40,931 by AM BV2014, 751,056 by BV 2018, 37,699 by BV 2018(B), 14,831 by AM BV2018 and 1,344,203 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were sold as follows: 355,406 by MPM BioVentures 2014, L.P. ("BV 2014"), 22,386 by MPM BioVentures 2014 (B), L.P. ("BV 2014(B)"), 12,233 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,467 by MPM BioVentures 2018, L.P. ("BV 2018"), 11,267 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 4,432 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 401,740 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC.

F2: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The shares are held as follows: 1,189,174 by BV 2014, 74,903 by BV 2014(B), 40,931 by AM BV2014, 751,056 by BV 2018, 37,699 by BV 2018(B), 14,831 by AM BV2018 and 1,344,203 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 02, 2021 Filed Nov 4, 2021 21:37 UTC	Entrada Therapeutics, Inc. TRDA · Entity 2163	ConversionSeries B Preferred Stock · Derivative	3,683,241	$0.00	$0.00	Disclosure SEC source: 0001209191-21-062982 · doc4.xml · derivative · entry 5 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 509,024 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date. F2 · price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date. F2 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date. F2 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date. F5 · ownership.nature: The shares were converted as follows: 231,139 by BV 2014, 15,417 by BV 2014(B), 7,956 by AM BV2014, 237,222 by BV 2018, 12,608 by BV 2018(B) and 4,682 by AM BV2018. Read SEC document
November 02, 2021 Filed Nov 4, 2021 21:37 UTC	Entrada Therapeutics, Inc. TRDA · Entity 2163	ConversionSeries A Preferred Stock · Derivative	27,617,675	$0.00	$0.00	Disclosure SEC source: 0001209191-21-062982 · doc4.xml · derivative · entry 4 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 3,816,760 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date. F2 · price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date. F2 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date. F2 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date. F1 · ownership.nature: The shares were converted as follows: 1,733,129 by MPM BioVentures 2014, L.P. ("BV 2014"), 115,596 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 59,655 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 1,778,737 by MPM BioVentures 2018, L.P. ("BV 2018"), 94,538 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 35,105 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. .. Read SEC document
November 02, 2021 Filed Nov 4, 2021 21:37 UTC	Entrada Therapeutics, Inc. TRDA · Entity 2163	PurchaseCommon Stock	100,000	$20.00	$2,000,000.00	Disclosure SEC source: 0001209191-21-062982 · doc4.xml · nonDerivative · entry 3 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,425,784 F7 · shares: The shares were purchased as follows: 45,408 by BV 2014, 3,029 by BV 2014(B), 1,563 by AM BV2014, 46,603 by BV 2018, 2,477 by BV 2018(B) and 920 by AM BV2018. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F8 · ownership.nature: The shares are held as follows: 2,009,676 by BV 2014, 134,042 by BV 2014(B), 69,174 by AM BV2014, 2,062,562 by BV 2018, 109,623 by BV 2018(B) and 40,707 by AM BV2018. Read SEC document
November 02, 2021 Filed Nov 4, 2021 21:37 UTC	Entrada Therapeutics, Inc. TRDA · Entity 2163	ConversionCommon Stock	509,024	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-062982 · doc4.xml · nonDerivative · entry 2 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,325,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: The shares were converted as follows: 231,139 by BV 2014, 15,417 by BV 2014(B), 7,956 by AM BV2014, 237,222 by BV 2018, 12,608 by BV 2018(B) and 4,682 by AM BV2018. F2 · price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F6 · ownership.nature: The shares are held as follows: 1,964,268 by BV 2014, 131,013 by BV 2014(B), 67,611 by AM BV2014, 2,015,959 by BV 2018, 107,146 by BV 2018(B) and 39,787 by AM BV2018. Read SEC document
November 02, 2021 Filed Nov 4, 2021 21:37 UTC	Entrada Therapeutics, Inc. TRDA · Entity 2163	ConversionCommon Stock	3,816,760	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-062982 · doc4.xml · nonDerivative · entry 1 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner GADICKE ANSBERT · CIK 0001134655 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,816,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The shares were converted as follows: 1,733,129 by MPM BioVentures 2014, L.P. ("BV 2014"), 115,596 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 59,655 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 1,778,737 by MPM BioVentures 2018, L.P. ("BV 2018"), 94,538 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 35,105 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. .. F2 · price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date. F3 · ownership.nature: The shares are held as follows: 1,733,129 by BV 2014, 115,596 by BV 2014(B), 59,655 by AM BV2014, 1,778,737 by BV 2018, 94,538 by BV 2018(B) and 35,105 by AM BV2018. F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. Read SEC document
October 18, 2021 Filed Oct 18, 2021 20:33 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	10,320	$27.14	$280,084.80	Disclosure SEC source: 0001209191-21-060722 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,137,214 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F9 · shares: The shares were sold as follows: 3,676 by BV 2014, 125 by AM BV2014, 2,321 by BV 2018, 45 by AM BV2018 and 4,153 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.96 to $27.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F11 · ownership.nature: The shares are held as follows: 1,771,303 by BV 2014, 107,713 by BV 2014(B), 60,967 by AM BV2014, 1,118,717 by BV 2018, 54,213 by BV 2018(B), 22,078 by AM BV2018 and 2,002,223 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
October 15, 2021 Filed Oct 18, 2021 20:33 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	3,413	$28.01	$95,598.13	Disclosure SEC source: 0001209191-21-060722 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,147,534 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F6 · shares: The shares were sold as follows: 1,215 by BV 2014, 42 by AM BV2014, 767 by BV 2018, 15 by AM BV2018 and 1,374 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.97 to $28.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: The shares are held as follows: 1,774,979 by BV 2014, 107,713 by BV 2014(B), 61,092 by AM BV2014, 1,121,038 by BV 2018, 54,213 by BV 2018(B), 22,123 by AM BV2018 and 2,006,376 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
October 15, 2021 Filed Oct 18, 2021 20:33 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	14,882	$27.53	$409,701.46	Disclosure SEC source: 0001209191-21-060722 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,150,947 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F2 · shares: The shares were sold as follows: 5,298 by MPM BioVentures 2014, L.P. ("BV 2014"), 182 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 3,347 by MPM BioVentures 2018, L.P. ("BV 2018"), 66 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 5,989 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F3 · shares: BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.97 to $27.955 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held as follows: 1,776,194 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 61,134 by AM BV2014, 1,121,805 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 22,138 by AM BV2018 and 2,007,750 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
October 14, 2021 Filed Oct 14, 2021 21:26 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	45,719	$27.30	$1,248,128.70	Disclosure SEC source: 0001209191-21-060489 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,165,829 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F9 · shares: The shares were sold as follows: 16,277 by BV 2014, 560 by AM BV2014, 10,280 by BV 2018, 203 by AM BV2018 and 18,399 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F11 · ownership.nature: The shares are held as follows: 1,781,492 by BV 2014, 107,713 by BV 2014(B), 61,316 by AM BV2014, 1,125,152 by BV 2018, 54,213 by BV 2018(B), 22,204 by AM BV2018 and 2,013,739 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
October 13, 2021 Filed Oct 14, 2021 21:26 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	35,023	$27.13	$950,173.99	Disclosure SEC source: 0001209191-21-060489 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,211,548 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F6 · shares: The shares were sold as follows: 12,469 by BV 2014, 429 by AM BV2014, 7,875 by BV 2018, 156 by AM BV2018 and 14,094 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.335 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: The shares are held as follows: 1,797,769 by BV 2014, 107,713 by BV 2014(B), 61,876 by AM BV2014, 1,135,432 by BV 2018, 54,213 by BV 2018(B), 22,407 by AM BV2018 and 2,032,138 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
October 12, 2021 Filed Oct 14, 2021 21:26 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	14,260	$27.09	$386,303.40	Disclosure SEC source: 0001209191-21-060489 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,246,571 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F2 · shares: The shares were sold as follows: 5,077 by MPM BioVentures 2014, L.P. ("BV 2014"), 175 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 3,206 by MPM BioVentures 2018, L.P. ("BV 2018"), 63 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 5,739 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F3 · shares: BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.28 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held as follows: 1,810,238 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 62,305 by AM BV2014, 1,143,307 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 22,563 by AM BV2018 and 2,046,232 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
October 11, 2021 Filed Oct 12, 2021 20:33 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	81,684	$27.24	$2,225,072.16	Disclosure SEC source: 0001209191-21-060235 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,260,831 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F9 · shares: The shares were sold as follows: 29,081 by BV 2014, 1,001 by AM BV2014, 18,367 by BV 2018, 363 by AM BV2018 and 32,872 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.53 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F11 · ownership.nature: The shares are held as follows: 1,815,315 by BV 2014, 107,713 by BV 2014(B), 62,480 by AM BV2014, 1,146,513 by BV 2018, 54,213 by BV 2018(B), 22,626 by AM BV2018 and 2,051,971 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
October 08, 2021 Filed Oct 12, 2021 20:33 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	3,400	$27.01	$91,834.00	Disclosure SEC source: 0001209191-21-060235 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,342,515 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F6 · shares: The shares were sold as follows: 1,210 by BV 2014, 42 by AM BV2014, 765 by BV 2018, 15 by AM BV2018 and 1,368 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.97 to $27.035 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: The shares are held as follows: 1,844,396 by BV 2014, 107,713 by BV 2014(B), 63,481 by AM BV2014, 1,164,880 by BV 2018, 54,213 by BV 2018(B), 22,989 by AM BV2018 and 2,084,843 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
October 07, 2021 Filed Oct 12, 2021 20:33 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	1,922	$27.00	$51,894.00	Disclosure SEC source: 0001209191-21-060235 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,345,915 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F2 · shares: The shares were sold as follows: 684 by MPM BioVentures 2014, L.P. ("BV 2014"), 24 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 432 by MPM BioVentures 2018, L.P. ("BV 2018"), 9 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 773 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F3 · shares: BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held as follows: 1,845,606 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 63,523 by AM BV2014, 1,165,645 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 23,004 by AM BV2018 and 2,086,211 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
October 04, 2021 Filed Oct 5, 2021 20:31 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	34,659	$27.06	$937,872.54	Disclosure SEC source: 0001209191-21-059421 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,347,837 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F6 · shares: The shares were sold as follows: 12,339 by BV 2014, 425 by AM BV2014, 7,793 by BV 2018, 154 by AM BV2018 and 13,948 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: The shares are held as follows: 1,846,290 by BV 2014, 107,713 by BV 2014(B), 63,547 by AM BV2014, 1,166,077 by BV 2018, 54,213 by BV 2018(B), 23,013 by AM BV2018 and 2,086,984 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
October 01, 2021 Filed Oct 5, 2021 20:31 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	11,471	$27.00	$309,717.00	Disclosure SEC source: 0001209191-21-059421 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,382,496 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F2 · shares: The shares were sold as follows: 4,084 by MPM BioVentures 2014, L.P. ("BV 2014"), 141 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 2,579 by MPM BioVentures 2018, L.P. ("BV 2018"), 51 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 4,616 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F3 · shares: BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held as follows: 1,858,629 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 63,972 by AM BV2014, 1,173,870 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 23,167 by AM BV2018 and 2,100,932 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
September 30, 2021 Filed Sep 30, 2021 21:05 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	3,836	$27.00	$103,572.00	Disclosure SEC source: 0001209191-21-058208 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,393,967 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F6 · shares: The shares were sold as follows: 1,366 by BV 2014, 47 by AM BV2014, 862 by BV 2018, 17 by AM BV2018 and 1,544 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.955 to $27.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: The shares are held as follows: 1,862,713 by BV 2014, 107,713 by BV 2014(B), 64,113 by AM BV2014, 1,176,449 by BV 2018, 54,213 by BV 2018(B), 23,218 by AM BV2018 and 2,105,548 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
September 28, 2021 Filed Sep 30, 2021 21:05 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	32,154	$27.00	$868,158.00	Disclosure SEC source: 0001209191-21-058208 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,397,803 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F2 · shares: The shares were sold as follows: 11,447 by MPM BioVentures 2014, L.P. ("BV 2014"), 394 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 7,230 by MPM BioVentures 2018, L.P. ("BV 2018"), 143 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 12,940 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F3 · shares: BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held as follows: 1,864,079 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 64,160 by AM BV2014, 1,177,311 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 23,235 by AM BV2018 and 2,107,092 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
September 27, 2021 Filed Sep 27, 2021 21:51 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	19,455	$27.09	$527,035.95	Disclosure SEC source: 0001209191-21-057822 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,429,957 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F12 · shares: The shares were sold as follows: 6,926 by BV 2014, 238 by AM BV2014, 4,375 by BV 2018, 86 by AM BV2018 and 7,830 by UBS Oncology. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.40 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F14 · ownership.nature: The shares are held as follows: 1,875,526 by BV 2014, 107,713 by BV 2014(B), 64,554 by AM BV2014, 1,184,541 by BV 2018, 54,213 by BV 2018(B), 23,378 by AM BV2018 and 2,120,032 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
September 24, 2021 Filed Sep 27, 2021 21:51 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	8,221	$27.81	$228,626.01	Disclosure SEC source: 0001209191-21-057822 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,449,412 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F9 · shares: The shares were sold as follows: 2,927 by BV 2014, 101 by AM BV2014, 1,849 by BV 2018, 36 by AM BV2018 and 3,308 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.39 to $28.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F11 · ownership.nature: The shares are held as follows: 1,882,452 by BV 2014, 107,713 by BV 2014(B), 64,792 by AM BV2014, 1,188,916 by BV 2018, 54,213 by BV 2018(B), 23,464 by AM BV2018 and 2,127,862 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
September 23, 2021 Filed Sep 27, 2021 21:51 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	1,200	$28.38	$34,056.00	Disclosure SEC source: 0001209191-21-057822 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,457,633 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F6 · shares: The shares were sold as follows: 427 by BV 2014, 15 by AM BV2014, 270 by BV 2018, 5 by AM BV2018 and 483 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.26 to $28.46 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: The shares are held as follows: 1,885,379 by BV 2014, 107,713 by BV 2014(B), 64,893 by AM BV2014, 1,190,765 by BV 2018, 54,213 by BV 2018(B), 23,500 by AM BV2018 and 2,131,170 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
September 23, 2021 Filed Sep 27, 2021 21:51 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	60,600	$27.96	$1,694,376.00	Disclosure SEC source: 0001209191-21-057822 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,458,833 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F2 · shares: The shares were sold as follows: 21,575 by MPM BioVentures 2014, L.P. ("BV 2014"), 743 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 13,626 by MPM BioVentures 2018, L.P. ("BV 2018"), 269 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 24,387 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F3 · shares: BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.25 to $28.24 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held as follows: 1,885,806 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 64,908 by AM BV2014, 1,191,035 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 23,505 by AM BV2018 and 2,131,653 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
September 22, 2021 Filed Sep 23, 2021 20:18 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	23,921	$27.54	$658,784.34	Disclosure SEC source: 0001209191-21-057413 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,519,433 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F6 · shares: The shares were sold as follows: 8,516 by BV 2014, 293 by AM BV2014, 5,379 by BV 2018, 106 by AM BV2018 and 9,627 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.03 to $27.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: The shares are held as follows: 1,907,381 by BV 2014, 107,713 by BV 2014(B), 65,651 by AM BV2014, 1,204,661 by BV 2018, 54,213 by BV 2018(B), 23,774 by AM BV2018 and 2,156,040 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
September 21, 2021 Filed Sep 23, 2021 20:18 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	32,858	$27.47	$902,609.26	Disclosure SEC source: 0001209191-21-057413 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,543,354 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F2 · shares: The shares were sold as follows: 11,698 by MPM BioVentures 2014, L.P. ("BV 2014"), 403 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 7,388 by MPM BioVentures 2018, L.P. ("BV 2018"), 146 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 13,223 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F3 · shares: BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.98 to $27.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held as follows: 1,915,897 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 65,944 by AM BV2014, 1,210,040 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 23,880 by AM BV2018 and 2,165,667 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
September 20, 2021 Filed Sep 20, 2021 22:30 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	22,930	$27.84	$638,371.20	Disclosure SEC source: 0001209191-21-056948 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,576,212 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F12 · shares: The shares were sold as follows: 8,163 by BV 2014, 281 by AM BV2014, 5,156 by BV 2018, 101 by AM BV2018 and 9,229 by UBS Oncology. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.53 to $28.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F14 · ownership.nature: The shares are held as follows: 1,927,595 by BV 2014, 107,713 by BV 2014(B), 66,347 by AM BV2014, 1,217,428 by BV 2018, 54,213 by BV 2018(B), 24,026 by AM BV2018 and 2,178,890 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
September 20, 2021 Filed Sep 20, 2021 22:30 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	17,743	$27.03	$479,593.29	Disclosure SEC source: 0001209191-21-056948 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,599,142 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F9 · shares: The shares were sold as follows: 6,317 by BV 2014, 217 by AM BV2014, 3,990 by BV 2018, 78 by AM BV2018 and 7,141 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.535 to $27.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F11 · ownership.nature: The shares are held as follows: 1,935,758 by BV 2014, 107,713 by BV 2014(B), 66,628 by AM BV2014, 1,222,584 by BV 2018, 54,213 by BV 2018(B), 24,127 by AM BV2018 and 2,188,119 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
September 17, 2021 Filed Sep 20, 2021 22:30 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	76,473	$28.82	$2,203,951.86	Disclosure SEC source: 0001209191-21-056948 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,616,885 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F6 · shares: The shares were sold as follows: 27,226 by BV 2014, 937 by AM BV2014, 17,195 by BV 2018, 340 by AM BV2018 and 30,775 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.50 to $29.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: The shares are held as follows: 1,942,075 by BV 2014, 107,713 by BV 2014(B), 66,845 by AM BV2014, 1,226,574 by BV 2018, 54,213 by BV 2018(B), 24,205 by AM BV2018 and 2,195,260 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
September 16, 2021 Filed Sep 20, 2021 22:30 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	35,565	$28.47	$1,012,535.55	Disclosure SEC source: 0001209191-21-056948 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,693,358 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F2 · shares: The shares were sold as follows: 12,662 by MPM BioVentures 2014, L.P. ("BV 2014"), 436 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 7,997 by MPM BioVentures 2018, L.P. ("BV 2018"), 158 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 14,312 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F3 · shares: BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.885 to $28.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held as follows: 1,969,301 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 67,782 by AM BV2014, 1,243,769 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 24,545 by AM BV2018 and 2,226,035 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
September 16, 2021 Filed Sep 20, 2021 21:30 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	3,124	$29.06	$90,783.44	Disclosure SEC source: 0001209191-21-056913 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,648,268 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
September 16, 2021 Filed Sep 20, 2021 21:30 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	432	$29.06	$12,553.92	Disclosure SEC source: 0001209191-21-056913 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,551 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 16, 2021 Filed Mar 25, 2022 23:32 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	GrantStock Option (Right to Buy) · Derivative	7,800	$0.00 Strike: $28.80	$0.00	Disclosure SEC source: 0000899243-22-012375 · doc4.xml · derivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2031-09-15 F1 · derivative.exercise_date: The option represents a right to purchase a total of 7,800 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 25, 2022 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date. Read SEC document
September 15, 2021 Filed Sep 16, 2021 20:46 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	1,659	$28.15	$46,700.85	Disclosure SEC source: 0001209191-21-056412 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,728,923 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F12 · shares: The shares were sold as follows: 591 by BV 2014, 20 by AM BV2014, 373 by BV 2018, 7 by AM BV2018 and 668 by UBS Oncology. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.13 to $28.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F14 · ownership.nature: The shares are held as follows: 1,981,963 by BV 2014, 107,713 by BV 2014(B), 68,218 by AM BV2014, 1,251,766 by BV 2018, 54,213 by BV 2018(B), 24,703 by AM BV2018 and 2,240,347 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
September 15, 2021 Filed Sep 16, 2021 20:46 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	38,677	$27.79	$1,074,833.83	Disclosure SEC source: 0001209191-21-056412 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,730,582 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F9 · shares: The shares were sold as follows: 13,770 by BV 2014, 474 by AM BV2014, 8,697 by BV 2018, 172 by AM BV2018 and 15,564 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.12 to $28.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F11 · ownership.nature: The shares are held as follows: 1,982,554 by BV 2014, 107,713 by BV 2014(B), 68,238 by AM BV2014, 1,252,139 by BV 2018, 54,213 by BV 2018(B), 24,710 by AM BV2018 and 2,241,015 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
September 15, 2021 Filed Sep 16, 2021 20:44 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	6,425	$29.16	$187,353.00	Disclosure SEC source: 0001209191-21-056409 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,651,392 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.43 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
September 15, 2021 Filed Sep 16, 2021 20:44 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	888	$29.16	$25,894.08	Disclosure SEC source: 0001209191-21-056409 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,983 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.43 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 14, 2021 Filed Sep 16, 2021 20:46 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	6,063	$27.99	$169,703.37	Disclosure SEC source: 0001209191-21-056412 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,769,259 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F6 · shares: The shares were sold as follows: 2,159 by BV 2014, 74 by AM BV2014, 1,363 by BV 2018, 27 by AM BV2018 and 2,440 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.92 to $28.055 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: The shares are held as follows: 1,996,324 by BV 2014, 107,713 by BV 2014(B), 68,712 by AM BV2014, 1,260,836 by BV 2018, 54,213 by BV 2018(B), 24,882 by AM BV2018 and 2,256,579 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
September 14, 2021 Filed Sep 16, 2021 20:46 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	30,018	$27.50	$825,495.00	Disclosure SEC source: 0001209191-21-056412 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,775,322 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F2 · shares: The shares were sold as follows: 10,687 by MPM BioVentures 2014, L.P. ("BV 2014"), 368 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 6750 by MPM BioVentures 2018, L.P. ("BV 2018"), 133 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 12,080 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F3 · shares: BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.91 to $27.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held as follows: 1,998,483 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 68,786 by AM BV2014, 1,262,199 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 24,909 by AM BV2018 and 2,259,019 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
September 14, 2021 Filed Sep 16, 2021 20:44 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	7,106	$29.17	$207,282.02	Disclosure SEC source: 0001209191-21-056409 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,657,817 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
September 14, 2021 Filed Sep 16, 2021 20:44 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	982	$29.17	$28,644.94	Disclosure SEC source: 0001209191-21-056409 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,871 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 13, 2021 Filed Sep 13, 2021 23:02 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	35,785	$27.64	$989,097.40	Disclosure SEC source: 0001209191-21-055745 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,805,340 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F12 · shares: The shares were sold as follows: 12,740 by BV 2014, 439 by AM BV2014, 8,046 by BV 2018, 159 by AM BV2018 and 14,401 by UBS Oncology. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.17 to $27.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F14 · ownership.nature: The shares are held as follows: 2,009,170 by BV 2014, 107,713 by BV 2014(B), 69,154 by AM BV2014, 1,268,949 by BV 2018, 54,213 by BV 2018(B), 25,042 by AM BV2018 and 2,271,099 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
September 13, 2021 Filed Sep 13, 2021 22:22 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	3,595	$29.10	$104,614.50	Disclosure SEC source: 0001209191-21-055725 · doc4.xml · nonDerivative · entry 6 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,664,923 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
September 13, 2021 Filed Sep 13, 2021 22:22 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	497	$29.10	$14,462.70	Disclosure SEC source: 0001209191-21-055725 · doc4.xml · nonDerivative · entry 5 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,853 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 10, 2021 Filed Sep 13, 2021 23:02 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	11,330	$28.73	$325,510.90	Disclosure SEC source: 0001209191-21-055745 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,841,125 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F9 · shares: The shares were sold as follows: 4,034 by BV 2014, 139 by AM BV2014, 2,547 by BV 2018, 51 by AM BV2018 and 4,559 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.46 to $28.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F11 · ownership.nature: The shares are held as follows: 2,021,910 by BV 2014, 107,713 by BV 2014(B), 69,593 by AM BV2014, 1,276,995 by BV 2018, 54,213 by BV 2018(B), 25,201 by AM BV2018 and 2,285,500 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
September 10, 2021 Filed Sep 13, 2021 23:02 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	11,313	$27.86	$315,180.18	Disclosure SEC source: 0001209191-21-055745 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,852,455 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F6 · shares: The shares were sold as follows: 4,027 by BV 2014, 139 by AM BV2014, 2,544 by BV 2018, 50 by AM BV2018 and 4,553 by UBS Oncology. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.455 to $28.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: The shares are held as follows: 2,025,944 by BV 2014, 107,713 by BV 2014(B), 69,732 by AM BV2014, 1,279,542 by BV 2018, 54,213 by BV 2018(B), 25,252 by AM BV2018 and 2,290,059 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
September 10, 2021 Filed Sep 13, 2021 22:22 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	5,931	$29.04	$172,236.24	Disclosure SEC source: 0001209191-21-055725 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,668,518 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.105 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
September 10, 2021 Filed Sep 13, 2021 22:22 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	820	$29.04	$23,812.80	Disclosure SEC source: 0001209191-21-055725 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,350 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.105 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 09, 2021 Filed Sep 13, 2021 23:02 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	38,028	$28.97	$1,101,671.16	Disclosure SEC source: 0001209191-21-055745 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,863,768 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F2 · shares: The shares were sold as follows: 13,539 by MPM BioVentures 2014, L.P. ("BV 2014"), 466 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 8,551 by MPM BioVentures 2018, L.P. ("BV 2018"), 169 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 15,303 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F3 · shares: BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.29 to $29.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held as follows: 2,029,971 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 69,871 by AM BV2014, 1,282,086 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 25,302 by AM BV2018 and 2,294,612 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
September 09, 2021 Filed Sep 13, 2021 22:22 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	13,727	$29.35	$402,887.45	Disclosure SEC source: 0001209191-21-055725 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,674,449 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
September 09, 2021 Filed Sep 13, 2021 22:22 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	1,898	$29.35	$55,706.30	Disclosure SEC source: 0001209191-21-055725 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,170 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 08, 2021 Filed Sep 8, 2021 23:19 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	1,573	$29.10	$45,774.30	Disclosure SEC source: 0001209191-21-055212 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,901,796 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F12 · shares: The shares were sold as follows: 560 by BV 2014, 19 by AM BV2014, 354 by BV 2018, 7 by AM BV2018 and 633 by UBS Oncology. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.04 to $29.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F14 · ownership.nature: The shares are held as follows: 2,043,510 by BV 2014, 107,713 by BV 2014(B), 70,337 by AM BV2014, 1,290,637 by BV 2018, 54,213 by BV 2018(B), 25,471 by AM BV2018 and 2,309,915 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.